Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats

Parkinsonism Relat Disord. 2007 Dec;13(8):524-7. doi: 10.1016/j.parkreldis.2006.11.005. Epub 2007 Jan 19.

Abstract

Background: This study investigated whether brief exposure to nitrous oxide (N(2)O) exacerbates levodopa-induced hyperhomocysteinemia, and if co-treatment with folate or entacapone could reduce total plasma homocysteine (tHcy) levels.

Methods: MALE WISTAR RATS (N=9 PER GROUP) WERE RANDOMLY TREATED WITH VEHICLE/N(2)O (GROUP 1), levodopa/nitrogen (group 2), levodopa/N(2)O (group 3), levodopa/N(2)O+folate (group 4), or levodopa/N(2)O+entacapone (group 5). tHcy was measured at 12 min, 4, 8, and 12 h after anesthesia.

Results and conclusion: The combination of N(2)O-exposure and levodopa treatment significantly increased tHcy in rats. This hyperhomocysteinemia could be prevented by entacapone but not folate co-administration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Non-Narcotic / pharmacology*
  • Analysis of Variance
  • Animals
  • Catechols / pharmacology
  • Drug Interactions
  • Enzyme Inhibitors / pharmacology
  • Homocysteine / blood
  • Hyperhomocysteinemia / blood
  • Hyperhomocysteinemia / chemically induced*
  • Immunoassay / methods
  • Levodopa*
  • Male
  • Nitriles / pharmacology
  • Nitrous Oxide / pharmacology*
  • Random Allocation
  • Rats
  • Rats, Wistar

Substances

  • Analgesics, Non-Narcotic
  • Catechols
  • Enzyme Inhibitors
  • Nitriles
  • Homocysteine
  • Levodopa
  • entacapone
  • Nitrous Oxide